Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫療控股有限公司
China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

PROFIT WARNING

This announcement is made by China Resources Medical Holdings Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement issued by the Company dated February 21, 2025 (the "**Yan Hua IOT Agreement Announcement**") in relation to the Yan Hua IOT Agreement Dispute. Unless otherwise defined, capitalized terms used herein shall have the same meanings given to them in the Yan Hua IOT Agreement Announcement.

The board (the "**Board**") of directors of the Company (the "**Director(s)**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that the Company is in the course of preparing its consolidated financial results for the six months ended June 30, 2026 (the "**Reporting Period**"). Based on information currently available to the Company and the preliminary review of the Group's unaudited consolidated management accounts for the Reporting Period, the Company expects that the profit attributable to the owners of the Company for the Reporting Period will be approximately RMB252 million to RMB278 million, representing a decrease of approximately 25.9% to 18.1% as compared to the profit attributable to the owners of the Company for the corresponding period in 2025; whereas, after excluding the one-off compensation for the management fees in previous years and the supply chain loss under the Yan Hua IOT Agreement of approximately RMB210 million received by the Group in 2025 (the "**Yan Hua Compensation**") and the corresponding enterprise income tax, the profit attributable to the owners of the Company would increase by approximately 36.2% to 50.6% as compared to the corresponding period in 2025. For further details of the Yan Hua IOT Agreement and the Yan Hua Compensation, please refer to the Yan Hua IOT Agreement Announcement. After excluding the effect of the Yan Hua Compensation and the corresponding enterprise income tax to the corresponding period in 2025, such expected increase in profit is mainly attributable to the increase in profit contributed by the member hospitals under the Company, which is benefitted from the Group's efforts in anchoring the core objective of improving quality and efficiency, optimizing cost structure, and continuously boosting operational management effectiveness. During the Reporting Period, the Group's volume of out-patient and emergency visits, inpatient visits and the proportion of Grade III/IV surgeries have increased, and the medical insurance management was further refined. In the second half of the year 2026, the Group will continue to proactively improve the revenue structure, strengthen the daily operations management of the member hospitals, and promote and enhance service quality and operational efficiency. The Group will actively respond to the changes in the external environment and solidify the foundation in general healthcare, while simultaneously exploring intelligent health services.

The Company is still in the process of finalising the Group's consolidated financial statements for the Reporting Period. The information contained in this announcement is only based on the information currently available to the Company and the preliminary assessment with reference to the unaudited consolidated management accounts of the Group for the Reporting Period, which are yet to be reviewed by the audit committee of the Company and the auditors of the Company.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company and are advised to refer to the details in the interim results announcement for the Reporting Period to be published by the Company before the end of August 2026.

By order of the Board of
China Resources Medical Holdings Company Limited
YU Hai
Chairman

PRC, August 12, 2026

As at the date of this announcement, the Board comprises Mr. YU Hai, Mr. ZHANG Chuang, Mr. WANG Yuexing and Mr. WU Xinchun as executive Directors; Mr. FANG Xin as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. FU Tingmei, Mr. ZHOU Peng and Ms. LO Wing Sze as independent non-executive Directors.